27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
- AstraZeneca Plc’s (NASDAQ:AZN) top-selling Tagrisso drug has been approved for use in the European Union to treat patients with a type of early-stage lung cancer.
- The European Commission has approved the lung cancer drug as an add-on (adjuvant) treatment for adults diagnosed early enough for the tumor to be surgically removed and have a mutation of the EGFR gene.
- The approval was based on positive results from a late-stage trial, ADAURA, which showed Tagrisso cut the risk of the tumor growing back in patients or death by 80%.
- Tagrisso brought in sales of $1.15 billion in the first quarter.
- Price Action: AZN shares are down 0.21% at $56.77 in the premarket session on the last check Friday.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!